LDH: The Unsung Hero in Multiple Myeloma Monitoring
"Why this simple blood test could be a game-changer in tracking disease progression."
Multiple myeloma (MM) is a type of cancer that affects plasma cells, which are a type of white blood cell responsible for producing antibodies. Monitoring the progression of multiple myeloma is crucial for effective treatment and improved patient outcomes. Traditionally, markers like beta-2 microglobulin and monoclonal immunoglobulin have been used to track the disease. But what if there's another, equally valuable marker hiding in plain sight?
Enter Lactate Dehydrogenase, or LDH. LDH is an enzyme found in nearly all living cells. It plays a critical role in cellular energy production. When cells are damaged, they release LDH into the bloodstream. Elevated LDH levels can indicate various conditions, from tissue damage to certain cancers. In the context of multiple myeloma, recent research suggests that LDH levels can provide valuable insights into disease progression and the development of extramedullary plasmacytomas (tumors outside the bone marrow).
This article explores the role of LDH as a useful clinical marker in monitoring multiple myeloma. We'll delve into a specific case report highlighting the significance of LDH levels and discuss what this means for early detection, treatment strategies, and patient care.
LDH in Risk Assessment
Multiple myeloma is the second most common hematologic cancer and remains incurable, according to a 2025 report. LDH is recognized as a prognostic factor, and the Revised International Staging System (R-ISS) incorporates LDH into staging for plasma cell myeloma. U.S. cancer data standards identify LDH as an AJCC 8th edition prognostic factor for plasma cell myeloma, including cases diagnosed from January 1, 2018 onward.
A Simple but Incomplete Marker
LDH can be measured with a simple blood test because cell damage or disease can release the enzyme into the bloodstream. Myeloma UK describes LDH as a useful indicator of tumor burden, staging, and prognosis, including within the R-ISS. Earlier research argued that elevated baseline LDH should be included alongside poor-risk cytogenetics and a high plasma cell labeling index when characterizing high-risk myeloma. The available sources support LDH as accessible and clinically useful, but they do not establish it as a standalone measure of disease status.
From Association to Biology
Research has associated elevated LDH with drug resistance and short survival in multiple myeloma. A 2018 study described myeloma as a heterogeneous disorder of clonal plasma cells and investigated the genomic basis of this association, noting that its biologic basis was uncertain. The same study focus was reported again in 2019, reinforcing the transition from observing LDH as a risk marker to examining the genomic features behind elevated LDH.
Understanding LDH and Multiple Myeloma
The original research, titled "Serum Level of Lactate Dehydrogenase is a Useful Clinical Marker to Monitor Progressive Multiple Myeloma Diseases: A Case Report," published in the Turkish Journal of Hematology in 2014, brings this lesser-known indicator into focus. The study highlights a case where LDH levels mirrored the disease's advancement, proving its potential as a marker similar to the established beta-2 microglobulin.
- Normal LDH at Diagnosis: The patient's LDH levels were within the normal range when she was first diagnosed, highlighting that normal levels don't necessarily rule out the presence of multiple myeloma.
- Dramatic Increase with Progression: As the disease advanced, LDH levels increased dramatically, exceeding 27 times the normal limit, indicating the proliferation of cancerous cells.
- Extramedullary Plasmacytomas: The development of tumors outside the bone marrow (extramedullary plasmacytomas) was associated with the sharp increase in LDH levels, suggesting that LDH can be a marker for this aggressive form of the disease.
- Fatal Outcome: Despite treatment, the patient's condition worsened, and she eventually passed away, emphasizing the need for vigilant monitoring and early intervention when LDH levels rise significantly.
Metabolism as a Therapeutic Target
Recent research is examining lactate metabolism in myeloma cells with elevated serum LDH. MCT1 mRNA and protein expression distinguished multiple myeloma cells from patients with elevated LDH from cells without elevated LDH. The study reported that dual inhibition of MCT1 and MCT4 disrupted lactate transport and showed preferential cytotoxicity in cells from patients with high serum LDH. Separately, contemporary reviews continue to discuss the technical and clinical evolution of measurable residual disease analysis and its opportunities and challenges for management.
Why LDH Requires Context
A high LDH result is not automatically synonymous with myeloma progression because LDH testing can involve false elevations and interpretation depends on reference ranges and clinical context. The available material also describes elevated LDH as an adverse prognostic marker that may prompt high-risk assessment, but it does not establish that every elevation should mandate a specific treatment approach. LDH should therefore be interpreted as one component of evaluation rather than as a standalone diagnosis or treatment directive.
A Marker Used in a Minority
The importance of LDH in multiple myeloma has been described for several decades. A 2023 report states that elevated LDH is detected in approximately 10% to 15% of patients at diagnosis. This places LDH in a clinically important but minority subgroup, making it particularly relevant for identifying patients whose disease may have more aggressive features.
What This Means for You
The research highlights the potential of LDH as a valuable tool in the fight against multiple myeloma. By monitoring LDH levels, healthcare professionals can gain a more comprehensive understanding of disease progression, detect extramedullary plasmacytomas early, and tailor treatment strategies for improved patient outcomes. This simple blood test could be a game-changer in how we approach multiple myeloma, offering hope for earlier intervention and better management of this challenging disease.
A Prognostic Signal in a Variable Disease
Multiple myeloma has substantial heterogeneity, with survival duration varying from a few months to several years. A retrospective study analyzed serum LDH in 105 patients with newly diagnosed myeloma, reflecting the effort to evaluate LDH within this broad clinical variation. LDH is therefore best understood as a prognostic signal that may help distinguish risk, not as a complete explanation of an individual patient's outcome.
Toward More Individualized Decisions
Future biomarker development is motivated by the need to stratify patients according to prognosis and therapeutic decision-making because current management has treated patients in broadly similar ways despite individual risk factors. Emerging multiple myeloma discussions from ASCO 2025 include advances in frontline therapy for transplant-eligible disease and trends in smoldering myeloma management. The 2026 outlook also highlights CAR-T therapy as a major area shaping survival discussions, although the supplied sources do not establish a specific LDH-guided CAR-T strategy.
Access and Interpretation
LDH may offer a relatively accessible way to add prognostic information to myeloma assessment, but its meaning depends on the broader clinical picture. Differences in laboratory practice, disease complexity, and access to specialized testing may affect how consistently results are interpreted. A practical approach is to use LDH as supportive information alongside other clinical and laboratory findings rather than treating it as a universal substitute for comprehensive evaluation.
A Changing Signal Over Time
A case report described a patient with a fulminant course whose LDH was normal at diagnosis and later increased to 27 times the normal level. The report presented serial LDH measurements as useful for following progressive multiple myeloma, alongside beta-2 microglobulin and monoclonal immunoglobulin. This case illustrates how a changing LDH level may provide clinically meaningful information over time, while remaining an individual case rather than a universal pattern.